CNS drug development in Europe - Past progress and future challenges

Neurobiology of Disease

Volumn 61, Issue , 2014, Pages 6-20

  Nutt, David J ^a   Attridge, Jim ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug development; Europe; Innovation incentives

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CITALOPRAM; DULOXETINE; FLUOXETINE; IMIPRAMINE; IPRONIAZID; LITHIUM; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIMELDINE;

ANXIETY DISORDER; BEHAVIOR DISORDER; BIPOLAR DEPRESSION; BRAIN FUNCTION; BUSINESS ETHICS; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE CLASSIFICATION; DOPAMINERGIC TRANSMISSION; DRUG CLASSIFICATION; DRUG COST; DRUG DEVELOPMENT; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; ELECTROCONVULSIVE THERAPY; EUROPE; GOOD CLINICAL PRACTICE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HISTORY OF MEDICINE; HUMAN; INCIDENCE; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; MOOD DISORDER; NEUROIMAGING; NEUROSCIENCE; NEUROTRANSMISSION; NORADRENALIN RELEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PROCESS TECHNOLOGY; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SUICIDAL IDEATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DRUG DEVELOPMENT; EUROPE; INNOVATION INCENTIVES;

CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; EUROPE; HUMANS; PSYCHOTROPIC DRUGS;

EID: 84888057150     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.05.002     Document Type: Review

References (56)

1. Abbott A. Schizophrenia: The Drug Deadlock [Online]Available at:, (Accessed 21 april 2012). http://www.nature.com/news/2010/101110/full/468158a.html.
2. Achilladelis B., Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Res. Policy 2001, 30:535-542.
3. Aghion P. A primer on innovation and growth - policy brief 6 2006, Breughel Institute, Brussels.
4. Anderson I.M., et al. Evidence based guidelines for treating depressive disorders: a revision of the 2000 British Association of Psychopharmacology Guidelines. J. Psychopharmacol. 2008, 22(4):343-396.
5. Andlin-Sobocki P., et al. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):1-27.
6. anon. List of Future Treatments for Depression, Anxiety, Sleep disorders Psychoses and ADHD s.l.:, (accessed on 15th January 2013). http://www.neurotransmitters.net/newdrugs.html.
7. Attridge J. Innovation policy in the EU: the biopharmaceutical sector. Innovation: How Europe can take-off 2011, Centre for European Reform, London. S. Tilford, P. Whyte (Eds.).
8. Benazzi F. Fluoxetine for the treatment of SSRI discontinuation syndrome. Int J Neuropsychopharmacol 2008, 11(5):725-726.
9. Bevan S. The Business Case for Employees Health and Wellbeing 2010, Investors in People UK, London.
10. Birnbaum H.G., et al. Employer burden of mild, moderate and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress. Anxiety 2010, 27:78-89.
11. Calfee J.E., DuPre E. The Emerging Market Dynamics of Targeted Therapeutics. Health Aff. 2006, 25(5):1302-1308.
12. Canadian Centre for Addiction and Mental Health The Unheralded Business Crisis in Canada - Depression at Work 2010, Canadian Centre for Addiction and mental Health, Toronto.
13. Coppola M., Mondola R. Methoxetamine: from drug of abuse to rapid-acting antidepressant. Med Hypotheses 2012, 79(4):504-507.
14. Cueni T. Can Europe afford Innovation?. EuroHealth 2008, 14:8-10.
15. DiMasi J.A., Paquette L. The economics of follow on drug R&D - trends in entry rates and timing of development. Pharmacoeconomics 2004, 22:1-6.
16. Docteur E. Pharmaceutical Pricing Policies in a Global Market 2008, OECD, Paris.
17. Domenici E., et al. Plasma protein biomarkers for depression and schizophrenia. PLoS One 2010, S(2):c9166. (accessed at www.plosone.org). 10.1371/journal.pone.0009166.
18. Drevets W., et al. Replication of scopolamine's antidepressant efficacy in major depressive disorder. Biol. Psychiatry 2010, 67:432.
19. Editorial, Nature A Decade of Psychiatric Disorders. Nature 2010, 463:9.
20. Eichler H.-G., et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat. Rev. Drug Discov. 2008, 10.1038/nrd2664.
21. European Commission Report on the High Level Pharmaceutical Forum 2005-2008 2008, European Commission, Brussels.
22. Gelijns A.C. Capturing the unexpected benefits of medical research. N. Engl. J. Med. 1998, 339(10):693-697.
23. Geoghan-Quinn M. Promoting innovation in an age of austerity: the European dimension. Innovation - How Europe can take off 2011, 43-44. Centre for European Reform, London. S. Tilford, P. Whyte (Eds.).
24. Girotra K., et al. Valuing R&D projects in a portfolio: evidence from the pharmaceutical industry. Manag. Sci. 2007, 53:1452-1466.
25. Gustavsson A. Cost of disorders of the brain in Europe. Eur. Neuropsychopharmacol. 2011, 21:718-779.
26. Harmer J., et al. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br. J. Psychiatry 2009, 195:102-108.
27. Hood S.D., et al. Antipsychotics. Psychiatry 2007, 6(7):295-300.
28. Huskamp Prices, profits and innovation: examining criticisms of new psychotropic drugs value. Health Aff. 2006, 25:635-646.
29. Isacsson G., Rich C. Antidepressant medication prevents suicide: a review of ecological studies. Eur. Psychiatr. Rev. 2008, 1:24-26.
30. Johnson B.A., et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 2011, 168:265-275.
31. Kennedy S.H., et al. Treating Depression Effectively 2007, Informa UK Ltd., London. 2nd ed.
32. Knapp M., et al. Mental Health Policy and Practice across Europe 2007, Open University Press, Milton Keynes.
33. Kremen R. Predicting drug response from brain waves. MIT Technol. Rev. 2009, (22). (September).
34. Landau R., et al. Footnote 25. Pharmaceutical Innovation - Revolutionising Human Health 1999, 216-217. Chemical Heritage Press, Philadelphia.
35. Laruelle M., Abi-Dargham A. Dopamine as the wind of psychotic fire; new evidence from brain imaging studies. J. Psychopharmacol. 1999, 13(4):358-371.
36. Mackram H., et al. Introducing the Human Brain Project. Brussels, The European Future Technologies Conference 2011.
37. Malizia A.L., et al. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry 1998, 55:715-720.
38. McCrone P., et al. Paying the Price - The Cost of Mental Healthcare in England in 2026 [Online]Available at:. http://www.kingsfund.org.uk.
39. Montgomery S., et al. Differential effects on suicidal ideation of mianserin. maprolitiline and amitriptyline. Br. J. Clin. Pharmacol. 1978, 5:77S-80S.
40. Nutt D., Attridge J. Innovation Processes in psychopharmacology and the implications for assessing the relative effectiveness of new products. J. Ment. Health Policy Econ. 2009, 12(Suppl. 1):S32.
41. Nutt D.J., Feetam C.L. What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. J. Psychopharmacol. 2010, 24:1137-1139.
42. Nutt D., Goodwin G. ECNP Summit on the Future of CNS Drug Research in Europe. Eur. Neuropsychopharmacol. 2011, 21:495-499.
43. Nutt D.J., Lowry C.A. How can we use current knowledge to improve antidepressant treatments?. Treating Depression: A Translational Approach 2009, Oxford University Press, Oxford. P. C.M. (Ed.).
44. Nutt D.J., Malizia A.L. New insights into the role of the GABA (A)-benzodiazepine receptor in psychiatric disorders. Br. J. Psychiatry 2001, 179:390-396.
45. Nutt D., Seddon K. Pharmacological treatment of bipolar disorder. Psychiatry 2007, 6(7):305-308.
46. Nutt D.J., Sinclair I. Anxiolytics. Psychiatry 2007, 284-288.
47. Nutt D.J., Stahl S.M. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J. Psychopharmacol. 2010, 24:1601-1612.
48. Perlis R.H. Betting on biomarkers. Am. J. Psychiatry 2011, 168(3):234-236.
49. Rost K., et al. Depression care management; can employers purchase improved outcomes. Volume Article ID 942519 2011.
50. Sainsbury Centre Report Mental Health at Work; Making the Business Case - Policy Paper 8 2010, Sainsbury Centre, London.
51. Schmidt H.D., et al. Functional biomarkers of depression: diagnosis, treatment and pathophysiology. Neuropsychopharmacology 2011, 36:151-154.
52. Schwartz M., Bahn S. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br. J. Pharmacol. 2008, 153:S133-S136.
53. Suhrcke M., McKee M. The Contribution of Health to the Economy of the European Union [Online]Available at:. http://www.europa.eu.int.
54. Tidd J., et al. Managing Innovation; Integrating Technological, Market and Organizational Change 2005, Wiley, New York. 3rd ed.
55. WHO Mental Health Report 2004, WHO, Geneva.
56. Wilsdon T., et al. Innovation in the Pharmaceutical Sector; A study undertaken for the European Commission by Charles River Associates [Online]Available at:. http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2004/nov.